Difference between revisions of "Team:Grenoble-Alpes/actors partnerships"

ACTORS AND PARTNERSHIPS

• HUMAN PRACTICES
  • ACTORS & PARTNERSHIPS
  • ETHICS
  • EVENTS
  • SAFETY & SECURITY

We discussed with a lot of people to develop our project, to better understand what is useful to implement, create and integrate into our project from their remarks.

GROUND FLOOR: We established partnerships with local companies like Biomérieux and local laboratories like TIMC in order to benefit from their advice/expertise and we had the opportunity to get some of their biological material. Our engineers and researcher partners gave us a lot of recommendations all along the summer and helped us to get an external point of view on our project.

FIRST FLOOR: We visited a medical analysis laboratory and we met the laboratory manager. We discussed with him about the detection system used in his laboratory and about the advantages and limits of our system, if it was used in this kind of laboratory.

SECOND FLOOR: We met with doctors and patients who talked with us about bacteriophages and antibiotic resistance. We discussed with them to know if our detection system could be used in hospitals and what modification we should make in order to improve it. You can have a look at them on the third floor (see our schematic below).

THIRD FLOOR: All the societies must be implicated in our project. But it’s /essential for us to be aware of what people know about phage therapy and antimicrobial resistance. It’s important to evaluate people's knowledge and then produce an appropriate outreach.

center>CLICK ON THE PEOPLE YOU WANT TO HEAR FROM ! Everybody has something interesting to share with you.

INTERVIEW WITH PR. MAX MAURIN

Dr. Max Maurin notes that in the last few years, he had to face new therapeutic dead-ends caused by the antibiotic resistance that did not exist before. The issue of antibiotic resistance is, in fact, a major issue that we should urgently address. Pseudomonas is a pathogen that he encounters quite often in his department. It is not too virulent but it has numerous resistance mechanisms. According to Dr. Maurin, phage therapy is a very interesting alternative even if it arises some ethical unsolved issues and can also cause a resistance of the bacteria toward phages. The use of bacteriophages in a medical establishment seems feasible because a few years ago, viruses were already used in the biological laboratory of hospitals.

Overall, Dr. Maurin thinks that our system is very interesting and answers well the given problem. However, some biological risks have to be taken into account such as the dissemination of the system components. If these aspects are well evaluated and handled, the system is very promising. Yet, Dr. Morin thinks that it will be very difficult to play on the sensitivity and the specificity of our system to compete with today’s methods in molecular biology. Among all the different specificities of our system, it is mostly the bacteriophages selection that caught his attention the most.

At last, Dr. Morin thinks that physicians do not have enough ethical formations and are not aware enough of new bioethical laws.